6 Biotech Stocks That Investors Hate but Analysts Love

Jacob Harper  |

Sometimes there are stocks that take a beating, but for whatever reason, the analysts won’t let them go. We decided to look at stocks that have had a rough go, but according to the analysts, are set to rebound any time. Specifically, for this article, we looked at the biotech sector.

Here’s the criteria we used: we decided to look at stocks that were down for the quarter but still had a “strong buy” rating from analysts. We further refined our search by focusing only on stocks above $4 a share to eliminate the more volatile ones.

We found six stocks that fit our criteria. Here they are:

Durata Therapeutics (DRTX) Chicago-based antibiotic developer Durata raised $74 million in an October 2012 IPO. Their main drug in development is dalbavancin, which treats skin infections. A December 2012 trial went well. Analysts still believe in the product’s future. Despite sitting near its 52 week low at $7 a share, Durata is up 1.74 percent.

Coronado Biosciences (CNDO) The immunotherapy drug development company is up 1.01 percent to $7.99 a share, and despite a dip the last few months, they’re up almost 67.58 percent on the year. Coronado recently announced they are hosting a conference looking for new investors.

Anacor Pharmaceuticals (ANAC) Anacor descirbes themselves as “hav(ing) discovered and advanced into clinical development several novel and proprietary boron-based product candidates.” They are up 4.34 percent to $5.53 a share. In June Anacor entered into a $45 million dollar term loan with Hercules Tech (HTGC.)

OncoGenex Pharmaceuticals (OGXI) OncoGenex gained 2.73 percent to hit $9.80 a share, though it’s down for the quarter and year (over 20 percent YTD.) Zacks is high on them, citing their drug OGX-011 that is “the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers.”

Lpath Inc. (LPTN) Lpath lost 1.94 percent to hit $4.56 a share, and is down for the year. This San Diego-based biotech company works on drugs that prevent macular degeneration. According to the New York Times, Lpath is advancing has completed a phase-I clinical trial for the drug ASONEP and is entering phase-II clinical trials in Renal Cell Carcinoma.

Array BioPharma(ARRY) Array is up 2.65 percent to hit $4.64 a share, down from their 52 week high of $6.56. Analysts are still bullish on the stock following promising trials for their p38 inhibitors that could have therapeutic effects on osteoarthritis.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Remote and Hybrid Work Is Boosting Commercial Air Travel
Silicon Valley ‘Open Secret’ Means Buy This World-Class Tech Stock
Natural Gas and Energy: Expect Dramatic Price Swings Near-Term
The Boulevard of Broken Dreams
Prepare For the December Oil Shock
Next Phase of Pharma Growth: Generics
Three Slam-Dunk Opportunities as the Inflation Nightmare Weakens
T-Mobile Was First to 5G Data, But Forgot Voice: Jeff Kagan

Market Movers

Sponsored Financial Content